Diagnosis and Drug Treatment of Alzheimer’s Disease in China is Low and Will Remain Low Through 2012

December 3, 2008

WALTHAM, Mass., Dec. 3 /PRNewswire/ — Decision Resources, one of the
world’s leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that the diagnosis and drug treatment of Alzheimer’s
disease in China is extremely low and will remain low through 2012,
particularly in rural regions. Although rural cases of Alzheimer’s disease
will account for approximately 70 percent of the prevalent Alzheimer’s disease
population in China in 2012, less than 10 percent of cases will be diagnosed
and even fewer will be treated with approved Alzheimer’s disease products.

“Public and professional awareness and prioritization of Alzheimer’s
disease in China is poor,” stated Jonathan Searles, analyst at Decision
Resources. “Patients and caregivers — and even physicians — across the
nation consider Alzheimer’s a natural part of aging and largely untreatable.
Coupled with the severe stigma attached to the disease and the high cost of
approved therapies, market opportunities for Alzheimer’s disease therapies in
China will remain constrained.”

The new Emerging Markets report entitled Alzheimer’s Disease in China also
finds that the Chinese Alzheimer’s disease drug market will continue to stay
untapped and underserved despite growing use of approved therapies. Huperzine
A (Chinese brands) and donepezil (Eisai’s Aricept, Chinese brands) dominated
the treatment of Alzheimer’s disease, together capturing nearly 80 percent
market share in 2007.

In spite of the continued dominance of costly therapies, including growing
use of memantine (Lundbeck’s Ebixa) — the most recently-launched and most
expensive Alzheimer’s disease therapy in China — the Chinese Alzheimer’s drug
market is expected to reach a mere $33 million in 2012, due chiefly to the
limited pool of treated patients and competition from older, entrenched

“Ultimately, patients and physicians in China — especially in rural
regions — will continue to rely heavily on more affordable and more familiar
traditional Chinese medicines, such as ginkgo leaf extracts, if
pharmacological therapy is sought at all,” added Mr. Searles.


The Ultimate Analysis of Pharmaceutical Markets in China and India

Decision Resources is the FIRST and ONLY company to offer a syndicated
report series for high-growth emerging markets with comprehensive
disease-specific analysis. Each report assesses the commercial opportunity in
the pharmaceutical market for a disease based on population demographics,
economic development, disease epidemiology and changing physicians’ practices.

About Decision Resources

Decision Resources (http://www.DecisionResources.com) is a world leader in
market research publications, advisory services and consulting designed to
help clients shape strategy, allocate resources and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com

SOURCE Decision Resources

Source: newswire

comments powered by Disqus